Business Wire

NY-IFF

15.4.2021 22:17:49 CEST | Business Wire | Press release

Share
IFF Presents “Learning Labs” Video Series to Demonstrate Potential of New Company

IFF (NYSE: IFF) today introduced a new “Learning Labs” video series, featuring in-depth discussions with the leadership of the company’s segments and R&D function. Each video provides a comprehensive overview of IFF’s robust portfolio and enhanced capabilities following its recently completed merger with DuPont’s Nutrition and Biosciences (“N&B”) business. The complete “Learning Labs” series can be found here: ir.iff.com/events-presentations . In addition, IFF has also provided segment-level financial detail based on 2020 pro forma results.

“As a global industry leader of high-value consumer ingredients, we are pleased to provide a closer look into our capabilities, operational model and future growth potential,” said Andreas Fibig, IFF Chairman and CEO. “Stakeholder communication remains essential to IFF’s continued growth, and since combining with N&B, we have continued to explore new ways to meaningfully connect with our investors. The insights shared through our ‘Learning Labs’ series and detail provided in our 2020 pro forma segment financials is a testament to our commitment to continued transparency and greater comparability to peers.”

IFF 2020 Pro Forma Segment-Level Financial Results

To accompany the “Learning Labs” video series, IFF has provided additional detail on the financial performance, including sales and adjusted EBITDA metrics, for each of the company’s four segments on a 2020 pro forma basis.

Welcome to IFF

At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .

International Flavors & Fragrances Inc.

2020 Pro Forma Combined Reporting Segments (1)(2)

(Dollars in millions)

 

Q1
2020 (3)

 

Q2
2020

 

Q3
2020

 

Q4
2020

 

Pro Forma
FY 2020 (excl.
N&B Jan.) (3)

 

Pro Forma
FY 2020 (4)

 

 

 

 

 

 

 

 

 

 

 

 

Nourish Pro Forma Sales

1,276

 

1,450

 

1,418

 

1,488

 

5,632

 

5,887

Nourish Pro Forma Adjusted Operating EBITDA

255

 

303

 

275

 

257

 

1,090

 

1,153

as % of Pro Forma Sales

20%

 

21%

 

19%

 

17%

 

19%

 

20%

 

 

 

 

 

 

 

 

 

 

 

 

Scent Pro Forma Sales

541

 

475

 

525

 

524

 

2,064

 

2,064

Scent Pro Forma Adjusted Operating EBITDA

118

 

87

 

118

 

93

 

416

 

416

as % of Pro Forma Sales

22%

 

18%

 

22%

 

18%

 

20%

 

20%

 

 

 

 

 

 

 

 

 

 

 

 

Health & Biosciences Pro Forma Sales

427

 

588

 

579

 

572

 

2,166

 

2,353

Health & Biosciences Pro Forma Adjusted Operating EBITDA

131

 

181

 

172

 

149

 

634

 

680

as % of Pro Forma Sales

31%

 

31%

 

30%

 

26%

 

29%

 

29%

 

 

 

 

 

 

 

 

 

 

 

 

Pharma Solutions Pro Forma Sales

152

 

224

 

215

 

188

 

779

 

839

Pharma Solutions Pro Forma Adjusted Operating EBITDA

42

 

62

 

61

 

38

 

203

 

216

as % of Pro Forma Sales

28%

 

28%

 

28%

 

20%

 

26%

 

26%

 

 

% Change in Sales - 2020 vs. 2019 (5)

 

 

Q1 (3)

 

Q2

 

Q3

 

Q4

 

 

Reported

Currency
Neutral

 

Reported

Currency
Neutral

 

Reported

Currency
Neutral

 

Reported

Currency
Neutral

Nourish

 

3%

5%

 

(4)%

(1)%

 

(5)%

(3)%

 

—%

1%

Scent

 

4%

7%

 

(6)%

—%

 

4%

9%

 

4%

6%

Health & Biosciences

 

8%

11%

 

(4)%

(2)%

 

(1)%

—%

 

1%

—%

Pharma Solutions

 

9%

11%

 

6%

7%

 

2%

1%

 

(2)%

(4)%

Total

 

4%

7%

 

(4)%

—%

 

(2)%

—%

 

1%

1%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pro Forma FY 2020
(excl. N&B Jan.) (3)

 

Pro Forma

FY 2020 (4)

 

 

 

 

 

 

 

 

Reported

Currency
Neutral

 

Reported

Currency
Neutral

 

 

 

 

 

 

Nourish

 

(2)%

—%

 

(2)%

—%

 

 

 

 

 

 

Scent

 

2%

5%

 

2%

5%

 

 

 

 

 

 

Health & Biosciences

 

—%

1%

 

—%

1%

 

 

 

 

 

 

Pharma Solutions

 

4%

3%

 

1%

1%

 

 

 

 

 

 

Total

 

—%

2%

 

(1)%

1%

 

 

 

 

 

 

_______________________

Note: Adjusted Operating EBITDA for each segment is defined as Income (Loss) Before Taxes before depreciation and amortization expense, interest expense, restructuring and other charges, net and certain non-recurring items. Additionally, all corporate expenses have been allocated to all of the reportable segments.

  1. The pro forma historical segment information has been presented for informational purposes only and is not necessarily indicative of what IFF's results of operations actually would have been, had the N&B transaction occurred on the dates indicated below. In addition, the pro forma historical segment information does not purport to project the future operating results of the Company.
  2. Dollar amounts may not foot due to rounding.
  3. The first quarter and Pro Forma FY 2020 (excl. N&B Jan.) show the combination of the historical results of IFF and N&B as if the N&B transaction had been consummated on February 1, 2020. Therefore, the first quarter and Pro Forma FY 2020 (excl. N&B Jan.) do not include the N&B business for the month of January 2020, which would allow comparability against the 2021 calendar year since the merger occurred on February 1, 2021. Total N&B Sales and Adjusted Operating EBITDA included in reportable segments for the month of January 2020 amounted to $502 million and $124 million, respectively.
  4. Pro Forma FY 2020 shows the combination of the historical results of IFF and N&B as if the N&B Transaction had been consummated on January 1, 2020. Therefore, Pro Forma FY 2020 includes a full twelve months of 2020 N&B and IFF results.
  5. Effective 2021, we calculate currency neutral growth by translating current year invoiced sale amounts at the average exchange rates used for the corresponding prior year period. Previously we calculated currency neutral numbers by comparing current year results to the prior year results restated at exchange rates in effect for the current year based on the currency of the underlying transaction.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Capcom’s Official Street Fighter 6 World Championship Tournaments Attract Record-high 20,000 Attendees16.3.2026 14:00:00 CET | Press release

– Capcom aims to accelerate growth of the global competitive scene with a larger total prize pool of over $2.1 million in the upcoming 2026 season – Capcom Co., Ltd. (TOKYO:9697) today announced that Capcom Cup 12 and Street Fighter League: World Championship 2025, its official world championship tournaments to determine the top Street Fighter 6 competitors, which were held at Ryogoku Kokugikan Arena from March 11-15, achieved a record-high of 20,000 attendees, concluding with great success. At Capcom Cup 12, which features matches against individual players, SAHARA (21 years old), who is a first‑year professional player, claimed the championship title in his debut appearance, while in the team-based competition Street Fighter League: World Championship 2025, Japanese representatives REJECT were the winning team. Capcom additionally announced that it will hold next season’s Capcom Cup 13 and Street Fighter League: World Championship 2026 at Ryogoku Kokugikan Arena. Furthermore, the com

Capcom’s Resident Evil Requiem Sales Exceed 6 Million Units!16.3.2026 14:00:00 CET | Press release

– Capcom also plans to release additional game content – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of Resident Evil Requiem, released on February 27, 2026, now exceed 6 million units, which is the fastest that a title in the series has reached this milestone. Resident Evil Requiem is the latest installment in the Resident Evil series, which offers photorealistic visuals and a deep sense of immersion. Players can enjoy the elevated essence of the survival horror experience by the interplay between intense fear and exhilarating action, made possible by two protagonists. Going forward, Capcom plans to implement several measures, such as ongoing support and additional game content, so players can continue to enjoy the title longer. In addition, the Resident Evil series will celebrate its 30th anniversary on March 22,2026. Capcom is readying various plans for this anniversary to delight series fans, such as a collaboration between Universal Studios Japan and Residen

Helical Fusion Announces Construction Site for Phase 1 of “Helix HARUKA,” Marking Transition to Manufacturing and Assembly of Fusion Hardware16.3.2026 14:00:00 CET | Press release

Advances one of Japan’s leading public-private partnership initiatives for fusion commercialization with NIFS and industrial partners Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; “Helical Fusion”), a Japanese fusion energy company advancing the Helix Program and developing the Helical Stellarator for commercial fusion power plants, announced the construction site for Phase 1 of Helix HARUKA, its Integrated Demonstration Device. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316066384/en/ Concept image of Helix HARUKA, Helical Fusion’s integrated demonstration device Phase 1—the magnet demonstration phase—will be built in a dedicated workspace for the joint research group formed by Helical Fusion and the National Institute for Fusion Science (NIFS), located on the NIFS campus. Helical Fusion has already begun manufacturing phase and site build-out, with the aim of conducting coil current (ene

HyperLight Demonstrates Low-Power 1.6T-DR8 TFLN-based Reference Transceiver Assembled by TFC16.3.2026 13:03:00 CET | Press release

HyperLight Corporation (“HyperLight”) today announced a major milestone in low-power optical networking with the demonstration of a 1.6T-DR8 optical transceiver leveraging HyperLight’s TFLN Chiplet™ Platform. The reference module was demonstrated with engineering and manufacturing support from Suzhou TFC Optical Communication Co., Ltd. (SZSE: 300394, or "TFC"). The reference design achieves 20W power consumption in a fully retimed 1.6T-DR8 module, representing approximately 20% lower module-level power compared to alternative technologies. The reduction is achieved through a simple drop-in transmitter implementation based on a single thin-film lithium niobate photonic integrated circuit (TFLN PIC). The TFLN transmitter enables the module to operate using a single continuous-wave (CW) laser, compared to the two to four lasers typically required in conventional implementations. Additional energy savings are achieved through the ability to operate directly from the native low-swing electr

GCE® Launches Gascontrol.com Website Showcasing Its Complete Gas Control Portfolio for Speciality, Medical, and Industrial Applications16.3.2026 13:00:00 CET | Press release

GCE®, a global market leader for gas control equipment, has launched gascontrol.com, a new website designed to better serve customers across its GCE Specialty, GCE Medical, and GCE Industrial product portfolios. The new site provides a streamlined, market-focused experience that makes it easier for users to explore GCE’s gas control solutions and identify the right products. A new Documentation Search Tool assists customers in easily finding documents such as instructions for use (IFUs), appendices, and certifications through an intuitive search interface. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316410525/en/ GCE’s new website, gascontrol.com, provides a streamlined, market-focused experience across the GCE Specialty, GCE Medical, and GCE Industrial product portfolios. “The redesigned website reflects GCE’s role as a comprehensive, trusted supplier of gas control technologies that elevate industries and improve liv

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye